Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

A few days later, confidence in the drug was dented again when Gilead Sciences called a halt to a mid-stage trial of islatravir given alongside its HIV capsid inhibitor lenacapavir, which is ...

namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591). The 36-patient CAPELLA trial tested lenacapavir in highly treatment-experienced HIV patients who had developed ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Please be advised that the Honourable Patty Hajdu, Minister of Indigenous Services, and the Honourable Ya'ara Saks, Minister ...

Gilead will present an overview of results from its pivotal Phase 3 PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials, which studied the efficacy and safety of lenacapavir, the company ...